Physician profile
Michael Anton Keller
NPI 1659572824
$50,312.05
in general payments reported to CMS, 2019-2025
29 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what 76% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $153 · 2021: $5,009 · 2022: $1,892 · 2023: $1,310 · 2024: $2,416 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,403 · Travel and Lodging: $1,649 · Education: $1,000 · Gift: $14.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,402.51 |
| Travel and Lodging | $1,648.93 |
| Education | $1,000.00 |
| Gift | $14.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $40,054.69 | 2019-2025 | Da Vinci Surgical System |
| Biom'Up Sa | $6,205.16 | 2019 | |
| Tela Bio, INC. | $1,737.75 | 2019-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Myriad Genetic Laboratories, INC. | $423.69 | 2022-2024 | Myrisk, Precisetumor |
| Biom'Up France Sas | $386.56 | 2020-2021 | |
| Medtronic, INC. | $264.79 | 2022-2024 | Interstim |
| Allergan, INC. | $161.96 | 2020-2022 | |
| Ethicon US, LLC | $153.39 | 2021-2025 | Vistaseal |
| Takeda Pharmaceuticals U.S.A., INC. | $143.50 | 2022-2023 | Gattex |
| Janssen Biotech, INC. | $124.99 | 2019 | |
| Baxter Healthcare | $121.69 | 2021 | |
| Integra Lifesciences Corporation | $70.72 | 2022-2025 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Abbvie INC. | $62.33 | 2023-2025 | |
| Vertex Pharmaceuticals Incorporated | $60.00 | 2025 | |
| Biotissue Holdings INC. | $51.21 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $48.70 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Davol INC. | $35.86 | 2024 | Phasix Mesh |
| Aroa Biosurgery Incorporated | $25.98 | 2025 | |
| Innovation Technologies INC | $21.78 | 2023 | Irrisept |
| Shire North American Group INC | $20.94 | 2019 | |
| Thd America, INC. | $19.86 | 2023 | |
| Smith+Nephew, INC. | $18.56 | 2023 | Stravix Pl |
| Acera Surgical, INC. | $18.51 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $18.19 | 2019 | |
| Sobi, INC | $17.75 | 2025 | |
| Tetraphase Pharmaceuticals, INC. | $16.08 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.77 | 2019 | |
| Acell, INC. | $13.64 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.